CymaBay Therapeutics Historical PE Ratio image   This CBAY PE ratio history page last updated 3/22/2024
CymaBay Therapeutics Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q4 2023
2/28/2024
32.27-0.35-1.40NA
Q3 2023
11/7/2023
16.44-0.32-1.28NA
Q2 2023
8/10/2023
12.96-0.01-0.04NA
Q1 2023
5/15/2023
10.40-0.29-1.16NA
Q4 2022
3/16/2023
9.14-0.30-1.20NA
Q3 2022
11/14/2022
3.61-0.28-1.12NA
Q2 2022
8/11/2022
3.74-0.31-1.24NA
Q1 2022
5/12/2022
1.78-0.32-1.28NA
Q4 2021
3/17/2022
3.18-0.34-1.36NA
Q3 2021
11/10/2021
4.28-0.33-1.32NA
Q2 2021
8/12/2021
3.96-0.34-1.36NA
Q1 2021
5/13/2021
4.12-0.25-1.00NA
Q4 2020
3/25/2021
4.59-0.23-0.92NA
Q3 2020
11/5/2020
8.50-0.17-0.68NA
Q2 2020
8/10/2020
6.90-0.16-0.64NA
Q1 2020
5/11/2020
1.84-0.19-0.76NA
Q4 2019
3/12/2020
1.41-0.43-1.72NA
Q3 2019
11/5/2019
5.19-0.38-1.52NA
Q2 2019
8/7/2019
5.56-0.35-1.40NA
Q1 2019
5/8/2019
12.75-0.37-1.48NA
Q4 2018
2/28/2019
11.81-0.32-1.28NA
Q3 2018
11/6/2018
10.91-0.34-1.36NA
Q2 2018
8/9/2018
11.64-0.30-1.20NA
Q1 2018
5/8/2018
12.30-0.32-1.28NA
Q4 2017
3/15/2018
12.49-0.11-0.44NA
Q3 2017
11/8/2017
8.33-0.21-0.84NA
Q2 2017
8/10/2017
6.66-0.31-1.24NA
Q1 2017
5/11/2017
3.62-0.20-0.80NA
Q4 2016
3/23/2017
3.81-0.30-1.20NA
Q3 2016
11/9/2016
1.45-0.25-1.00NA
Q2 2016
8/9/2016
1.79-0.30-1.20NA
Q1 2016
5/11/2016
2.40-0.29-1.16NA
Q4 2015
3/29/2016
1.41-0.26-1.04NA
CymaBay Therapeutics PE History Chart
PeriodPriceGAAPTTMPE
Q4 2023
2/28/2024
32.27-0.35-0.97NA
Q3 2023
11/7/2023
16.44-0.32-0.92NA
Q2 2023
8/10/2023
12.96-0.01-0.88NA
Q1 2023
5/15/2023
10.40-0.29-1.18NA
Q4 2022
3/16/2023
9.14-0.30-1.21NA
Q3 2022
11/14/2022
3.61-0.28-1.25NA
Q2 2022
8/11/2022
3.74-0.31-1.30NA
Q1 2022
5/12/2022
1.78-0.32-1.33NA
Q4 2021
3/17/2022
3.18-0.34-1.26NA
Q3 2021
11/10/2021
4.28-0.33-1.15NA
Q2 2021
8/12/2021
3.96-0.34-0.99NA
Q1 2021
5/13/2021
4.12-0.25-0.81NA
Q4 2020
3/25/2021
4.59-0.23-0.75NA
Q3 2020
11/5/2020
8.50-0.17-0.95NA
Q2 2020
8/10/2020
6.90-0.16-1.16NA
Q1 2020
5/11/2020
1.84-0.19-1.35NA
Q4 2019
3/12/2020
1.41-0.43-1.53NA
Q3 2019
11/5/2019
5.19-0.38-1.42NA
Q2 2019
8/7/2019
5.56-0.35-1.38NA
Q1 2019
5/8/2019
12.75-0.37-1.33NA
Q4 2018
2/28/2019
11.81-0.32-1.28NA
Q3 2018
11/6/2018
10.91-0.34-1.07NA
Q2 2018
8/9/2018
11.64-0.30-0.94NA
Q1 2018
5/8/2018
12.30-0.32-0.95NA
Q4 2017
3/15/2018
12.49-0.11-0.83NA
Q3 2017
11/8/2017
8.33-0.21-1.02NA
Q2 2017
8/10/2017
6.66-0.31-1.06NA
Q1 2017
5/11/2017
3.62-0.20-1.05NA
Q4 2016
3/23/2017
3.81-0.30-1.14NA
Q3 2016
11/9/2016
1.45-0.25-1.10NA
Q2 2016
8/9/2016
1.79-0.30NANA
Q1 2016
5/11/2016
2.40-0.29NANA
Q4 2015
3/29/2016
1.41-0.26NANA
Quotes delayed 20 minutes

Email EnvelopeFree CBAY Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
CymaBay Therapeutics (CBAY) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

CBIO PE Ratio History
CBUS PE Ratio History
CCCC PE Ratio History
CCEL PE Ratio History
CCRN PE Ratio History
CCXI PE Ratio History
CDAK PE Ratio History
CDMO PE Ratio History
CDNA PE Ratio History
CDRE PE Ratio History
How should the CBAY historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like CymaBay Therapeutics. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this CBAY Historical PE Ratio page.

What is the average historical PE for CBAY based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The CBAY historical PE ratio using the annualized quarterly earnings method works out to NA.

What is the average historical PE for CBAY based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The CBAY historical PE ratio using the TTM earnings method works out to NA.

On this page we presented the CymaBay Therapeutics Historical PE Ratio information for CymaBay Therapeutics' stock. The average CBAY historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average CBAY historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this CBAY historical PE result, against the recent PE: when this page was posted on 3/21/2024, the most recent closing price for CBAY had been 32.48, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on CBAY or any other given stock, valuation analysis for CBAY can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate CymaBay Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for CBAY. Thanks for visiting, and the next time you need to research CBAY Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: HCRB Videos, DGHI YTD Return, Funds Holding FEIM.

 

CymaBay Therapeutics Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2024, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 9.5%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 9.5%.